Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 36, Issue 2, 2003, Pages 261-265

  Madrazo De La Garza, Armando ^a   Dibildox, Miguel ^b   Vargas, Antonio ^b   Delgado, Juan ^a   Gonzalez, Jorge ^b   Yañez, Patricia ^a  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

^b ALTANA Pharma Mexico ^*  (Mexico)

Author keywords

Children Reflux esophagitis 24 hour pH metry Pantoprazole Proton pump inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GASTRIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; OMEPRAZOLE; SULFOXIDE;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS BIOPSY; ESOPHAGUS PH; FEMALE; GASTRIN BLOOD LEVEL; GASTROINTESTINAL ENDOSCOPE; GASTROINTESTINAL SYMPTOM; HEALING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGASTRINEMIA; LIVER DYSFUNCTION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SCORING SYSTEM; STOMACH ACID SECRETION; STOMACH PH; VANDENPLAS CLASSIFICATION; CHEMISTRY; DRUG EFFECT; ESOPHAGUS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PH; SAFETY; TIME; TREATMENT OUTCOME;

ACRONICTA LEPORINA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CHILD; ESOPHAGITIS, PEPTIC; ESOPHAGUS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; SAFETY; SULFOXIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038205409     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200302000-00019     Document Type: Article

References (27)

1. Madrazo de la Garza JA, Gonzalez OB. [Gastroesophageal reflux in pediatrics]. Rev Gastroenterol Mex 1994;59:114-9.
2. Zimmermann AE, Walters JK, Katona BG, Souney PE, Levine D. A review of omeprazole use in the treatment of acid-related disorders in children. Clin Ther 2001;23:660-79.
3. Byrne MF, Murray FE. Formulary management of proton pump inhibitors. Pharmacoeconomics 1999;16:225-46.
4. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastrooesophageal reflux disease in general practice. BMJ 2001;322:344-7.
5. Fennerty MB, Lieberman D. H2-receptor antagonists in the treatment of complicated gastroesophageal reflux disease: 'for whom the bell tolls'. Gastroenterology 1994;107:1545-8.
6. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
7. Bardhan KD. Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease. Drugs of today 1999;35:773-808.
8. Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995;56:443-54.
9. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996;8 Suppl 1:S21-5.
10. Steinijans VW, Huber R, Hartmann M et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996;34:S31-S50.
11. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994;8 Suppl 1:33-8.
12. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995;9:363-78.
13. Kromer W, Horbach S, Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999;59:57-77.
14. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82.
15. Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998;27:568-79.
16. Hassall E, Israel D, Shepherd R et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000;137:800-7.
17. Gupta SK, Tolia VK, and Heyman MB. Adolescent pafients with gastroesophageal reflux disease (GERD): result from a randomized trial of lansoprazole (abstract). Gastroenterology 2000;118 Suppl. 2 (Pt. 2):1242.
18. Tolia VK, Ferry G, and Gunasekaran TS. Efficacy of lansoprazole in the treatment of GERD in children (abstract). Am J Gastroenterol 2000;95:2446.
19. Tolia VK, Fitzgerald J, and Hassall E. Safety of lansoprazole in the treatment of GERD in children (abstract). Am J Gastroenterol 2000;95:2447.
20. Franco MT, Salvia G, Terrin G et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32:660-6.
21. Faure C, Michaud L, Shaghaghi EK et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402.
22. Vandenplas Y. Reflux esophagitis in infants and children: a report from the Working Group on Gastro-Oesophageal Reflux Disease of the European Society of Paediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1994;18:413-22.
23. Savary M, Miller G. The esophagus. In: Savary M, Miller G, eds. In: Handbook and atlas of endoscopy. Solothurn, Switzerland: Verlag Gassman AG, Solothurn, Switzerland; 1978p. 119-205.
24. Andersson T, Hassall E, Lundborg P et al. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000;95:3101-6.
25. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54.
26. Beck IT, Champion MC, Lemire S et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997;11 (Suppl B):7B-20B.
27. Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999;13 Suppl 5:5-10.